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Background: The aim of this study was to assess the efficacy and safety of totally implanted vascular devices
(TIVAD) using different techniques of insertion.
Methods: We performed a retrospective study using a prospective collected database of 796 consecutive
oncological patients in which TIVADs were inserted. We focused on early and late complications following different
insertion techniques (surgical cutdown, blind and ultrasound guided percutaneous) according to different
techniques.
Results: Ultrasound guided technique was used in 646 cases, cephalic vein cutdown in 102 patients and
percutaneous blind technique in 48 patients. The overall complication rate on insertion was 7.2% (57 of 796 cases).
Early complications were less frequent using the ultrasound guided technique: arterial puncture (p = 0.009),
technical failure (p = 0.009), access site change after first attempt (p = 0.002); pneumothorax occurred in 4 cases, all
using the blind percutaneus technique. Late complications occurred in 49 cases (6.1%) which required TIVAD
removal in 43 cases and included: sepsis (29 cases), thrombosis (3 cases), dislocation (7 cases), skin dehiscence
(3 cases), and severe pain (1 case).
Conclusion: Ultrasound guided technique is the safest option for TIVAD insertion, with the lowest rates of
immediate complications.
Keywords: Totally implantable venous access device, US guided, ChemotherapyBackground
The use of totally implantable venous access devices
(TIVADs) has changed the care and quality of life for
cancer patients treated with chemotherapy. TIVADs
represent a convenient option when long-term venous
access is indicated, particularly for administration of
cytotoxic medications or intravenous targeted agents in
cancer patients over a long period of time [1]. The
current debate regarding TIVAD utilisation in clinical* Correspondence: marcoscarpa73@yahoo.it;
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reproduction in any medium, provided the orpractice includes the access site (internal, external jugular
and subclavian vein) and the insertion technique (open,
percutaneous or with ultrasound guidance). Cephalic vein
approach has the advantage of safety and low incidence of
early complications [2] but it is affected by a high rate of
failure. Subclavian vein catheters are located in an easy
accessible area but they are affected by a relatively high
risk of thrombosis, vein stenosis, catheter fatigue and they
have the highest risk of pneumothorax at insertion [3].
The internal jugular approach is the preferred approach
for tunnelled infusion catheter approach with the lowest
incidence of venous thrombosis [4]. Usually percutaneus
techniques through the Seldinger technique are preferred
[5-7] but in some cases surgeons prefer the open approachal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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include: pneumothorax, hemothorax, air embolism, acci-
dental arterial puncture, cardiac arrhythmia, pericardial
tamponade and brachial plexus injury [8,9]. Late complica-
tions include: bloodstream infection, thrombosis, catheter
dysfunction, rupture, migration or embolisation, “pinch-off”
syndrome, superior vein cava erosion and perforation,
extravasation, pocket infection and port inversion [10-12].
The refinement of the technique and the implanted devices
led to a decreased rate of potential life threatening com
plications.
The aim of this study was to evaluate the short and long
term outcomes after TIVAD implantation in a, consecu-
tive series of patients by comparing the different insertion
techniques.Methods
Study design
The study was performed according to the second prin-
ciples of the Declaration of Helsinki. The study was
retrospectively reviewed and approved by the Ethical
Committee of the Veneto Institute of Oncology (protocol
number 0001897; Internal code: 2014/13/NOTIFICA; date
of approval 24th February 2014). This study is a retro-
spective review of a prospectively collected database cre-
ated in 2006 by the authors including 796 consecutive
totally implantable venous access devices (TIVAD) applied
from November 2006 to November 2011 in the Surgical
Oncology Unit of the Veneto Institute of Oncology (IOV-
IRCCS). Follow up continued until the device was removed,
patient died or the study was closed (30.11.2011). Patients
gave their informed consent to have their data collected in a
database and to have them anonymously used for scientific
purposes. The devices were implanted in adult patients
affected by several different neoplastic diseases requiring
chemotherapy. All patients had the same type of TIVAD
implanted: an M.R.I. Implantable Port with open end 8
French polyurethane single lumen venous catheter (C. R.
Bard, Inc. Murray Hill, New Jersey, USA). The main tumor
types were gastrointestinal, breast, head and neck, ovarian
and sarcoma.
Preoperative evaluation included medical history and
physical examination, focusing on possible anatomic
pitfalls (cervical or mediastinal adenopathy, chest wall
tumours, previous neck or thoracic surgery), body hab-
itus, previous vascular access placements and complica-
tions. Laboratory studies consisted in full blood count
and coagulation. Exclusion criteria were platelet count <
80.000/mm3, INR > 1.5, neutrophil count <1000/mm3,
fever or sepsis. During the pre-treatment visit patients
were informed on the procedure, risks, benefits, data
management and follow up, and written informed con-
sent for the inclusion in this study was obtained.Data collection and follow-up
A score of procedural difficulty was assigned to each
TIVAD implantation, ranging from 1 (easy) to 4 (extremely
difficult). Patient characteristics, which included diagnosis,
indication for catheter placement, age, height, weight,
results of laboratory test parameters and current medica-
tions were recorded. Device type, site of venous access,
surgeon and anaesthesiologist performing the procedures
and placement complications were documented. Data
from hospital admissions and telephone follow-up were
recorded at regular intervals and prospectively collected in
a database. All device-associated complications were re-
corded during follow up. Complications were classified
into two main categories: early (intraoperative and post-
implantation period to first use) and late complications
(occurring after the first chemotherapy course adminis-
tered through the device).
Criteria for the diagnosis of device-related bacteraemia
were defined as follows: a over 10-fold increase in
colony-forming units (CFU) of bacteria per ml of blood
obtained through the device in comparison to peripheral
blood cultures; over 1000 CFU of bacteria obtained
through the device, in the absence of peripheral blood
cultures; or positive catheter tip culture upon removal in
the appropriate clinical setting. Port pocket infection
was defined by induration, erythema and tenderness
around the port with culture-positive material aspirated
from the port pocket. Cutaneous site infection was
defined by induration, erythema, or tenderness and ex-
udate at the port surface needle access site. Thrombosis
was detected with ultrasound and/or venography when
clinically suggested by progressive arm or facial swelling.
The following assumptions were used as the basis for de-
termining the cost-effectiveness of each strategy. Operative
room hourly costs were based on current estimates of
standard charges in an Italian setting (2013), including sal-
aries for a surgeon, a anesthesiologist and two nurses (650
euro per hour). We calculated the overall cost for our
institution.
Implantation techniques
Devices were implanted in the operating room, using max-
imal sterile-barrier precautions, under local anaesthesia, ad-
ministering a mixture of Lidocaine 1% and Ropivacaine
0.5% and employing fluoroscopic control. Premedication
with midazolam 0.01-0.035 mg/kg (1–3 mg) was provided
in case of patient anxiety. A single dose of Cefazoline 2 g
was administered intravenously before the procedure. In
beta-lactam allergic patients, Vancomycin 15 mg/kg was
used. In order to prevent clot formation and catheter block-
age, TIVAD were flushed with 20 ml saline and then filled
with 5 ml of a solution containing 50 U/ml heparin. Stand-
ard protocol was to flush all the devices with heparinized
saline solution after use and on a monthly outpatient basis.




Age (years, median/range) 61 (21–87)
Gender (F/M) 432/364
Body Mass Index (kg/m2, median, range IQR) 24.23 (21.9-27.18)
Follow up (weeks, median, range IQR) 35.14 (23–55.4)
Follow up completed (n° pts/total pts) 535/796
Length of use (weeks, median, range IQR) 22.71 (10.1-41.9)
Time of in-situ permanence (weeks, median,
range IQR)
33.71 (15.71-57)
















White blood cells count (cells ×109/L, median,
range IQR)
6 (1.98-8.77)
Hb (g/L, median, range IQR) 12 (10–13)
Platelets (cells × 109/L, median, range IQR) 276 (223–341.5)
PT (%, prothrombin time, median, range IQR) 88 (75–100)
PTT (sec, partial thromboplastin time, median,
range IQR)
28 (26–30)
INR (international normalized ratio, median,
range IQR)
1,00 (0.5-1.12)
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From November 2006 until January 2008 devices were
placed using either a cephalic vein cut-down or a blind
percutaneous approach based on anatomic landmarks.
The choice of insertion technique was at the discretion
of the surgeon. Since January 2008 the percutaneous ap-
proach was improved using ultrasound guidance.
Cut-down approach
A single incision was made in the upper anterior chest
wall along the delto-pectoral groove as first described by
Heimbach and Ivey [13]. The cephalic vein was identi-
fied and isolated between 2 vessel loops. The catheter
was then directly inserted into the cephalic vein through
a transverse venotomy. The distal cephalic vein was tied
off. The reservoir was inserted superficially into a subcuta-
neous pocket, with the device located just inferior to the
skin incision. Fluoroscopy was used to confirm positioning
of the tip of the catheter at the cavo-atrial junction. No
additional postoperative radiographs were performed.
“Blind” percutaneous technique
The preferred access site was the subclavian vein (SV).
The internal jugular vein (IJV) was chosen when SV can-
nulation was contraindicated for anatomic pitfalls. A Sel-
dinger technique was used to access the vein with
dilators and peel away sheaths for the insertion. In case
of subclavian vein cannulation, the site of puncture was
at the inferior border of the clavicle, between the middle
and the lateral third of it, directed toward the fingertip
pressed firmly into the suprasternal notch. The needle
passed beneath the inferior margin of the clavicle in a
horizontal plane and directed toward the anterior mar-
gin of the trachea at the level of the suprasternal notch.
The internal jugular vein was cannulated at the top of
the triangle between the sternal and clavicular head of
the sternocleidomastoid muscle, advancing the needle
through the skin at a 45° angle in the direction of the
omolateral nipple. Fluoroscopy confirmed the position
of the catheter at the cavo-atrial junction, and a comple-
tion upright chest radiograph was performed before
leaving the surgical ward to assess for the presence of
pneumothorax. Usually 2 incisions were necessary: a
small incision at the catheter exit site from the skin and
a second larger incision for location of the implantable
access device. A subcutaneous tunnel was made to pass
the catheter from 1 incision to the other.
Ultrasound guided percutaneous technique
A 7–12 MHz linear-array ultrasound probe connected
to a real-time ultrasound unit (General Electric Logiq®
P5, GE Healthcare Clinical Systems SrL,), and focused at
2–4 cm depth, was covered with ultrasonic gel and
wrapped in a sterile plastic sheath. Standard ultrasoundtwo-dimensional (2D) imaging was used to measure the
depth and calibre of the IJV or SV, evaluate its patency
and compressibility. In cases of pre-existing thrombus
formation and/or failure to gain access due to trauma or
other anatomical anomalies, the IJV or SV on the controlat-
eral side was catheterised. Catheterisation was performed
under continuous dynamic observation of real-time 2D
images. The in-plane approach was used to achieve a long-
axis view of the needle, allowing full visualization of the
shaft and tip of the needle. The low lateral approach, as
described by Jernigan and modified by Pittiruti [14], was
used to obtain cannulation of the distal IJV, or whenever
Table 2 Characteristic of patients divided in groups according to the implantation technique (Intention To Treat)
Characteristic (SC) (BP) (US) p- value
(102 pts) (48 pts) (646 pts)
Age (years, median/range) 60 61 61 0.478
Gender (M/F) 52/50 15/33 297/349 0.07
Body Mass Index (kg/m2, median, range IQR) 25.3 (22.4-27.3) 28.3 (24.9-30.9) 24.2 (21.9-28.8) 0.003
Follow up (weeks, median range IQR) 81 (66–94) 106 (98–118) 31 (20–46) <0.001
Follow up completed (n° pts/total pts) 76/102 31/48 413/646 0.288
Time of in-situ permanence (weeks, median, range IQR) 38.8 (25.1-57.8) 70.6 (51.6-96.2) 25.3 (13.1-47.1) 0.001
Operating time (min, median, range IQR) 45 (40–60) 45 (40–60) 30 (20–40) <0.001
Costs (euro median IQR) 487.5 (429–650) 487.5 (429–650) 325 (214.5-429) <0.001
Score of difficulty (median range IQR,) 1 (1–2) 1 (1–1) 1 (1–1) 0.046
Surgical Cutdown: SC; Blind Percutaneus technique: BP; US guided Percutaneous technique: US.
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the brachiocephalic vein was obtained giving to the ultra-
sound probe a caudal direction, placing it with an inclin-
ation of 20–30 degrees with the neck and the clavicle. The
ultrasound-guided subclavian vein catheterisation was
performed positioning the probe below the clavicle, usually
in the lateral third, to obtain a long axis of the vein. Using
an in plane approach, the SV was cannulated just medially
to the junction of cephalic vein to the axillary vein. An 18-
gauge, 7-cm needle was advanced through the skin under
ultrasound guidance into the vein. A guidewire was then
placed through the needle into the vein, and the needle was
removed. Fluoroscopy confirmed the position of the cath-
eter at the cavo-atrial junction, considering an optimal pos-
ition when the catheter tip was located within a range of
2 cm at the lower border of the right main bronchus. Also
in this case, 2 incisions were necessary: 1 small incision at
the wire exit site from the skin and a second larger incision
for location of the implantable access device. A subcutane-
ous tunnel was made to pass the catheter from 1 incision
to the other. No additional postoperative radiographs were
performed except in case of repeated attempts or proced-
ural complications.Table 3 Anatomic site for venous access
Successful vein accessed Number
Cephalic vein Right 19
Left 74
Proximal internal jugular vein (cervical access) Right 68
Left 39
Subclavian vein Right 16
Left 65





Statistical analysis was performed using both Microsoft
Excel and STATISTICA 7.1 software (Statsoft, Tulsa, OK,
USA). Continuous data are expressed as medians and
interquartile ranges, while dichotomic data are expressed
as frequencies and proportions. Continuous data were
compared with two tailed Mann-Whiteny U test or
Kruskall-Wallis ANOVA where appropriate, while fre-
quencies were compared with Fisher's exact test or Chi
square analysis. Odds ratios were calculated to assess the
risk of complication. Only predictors resulting significant
at univariate analysis were included in multivariate




Overall characteristics of the study population and divided
by the insertion technique are shown in Tables 1 and 2.
The majority of patients had solid organ cancer; only 29
(3.64%) had hematologic malignancies (lymphoma). The
median follow up was 35.1 (23.0-55.4) weeks. During the
period of our study three different implantation tech-
niques were used. In the first part of our study, we utilised
the surgical cutdown or blind percutaneus according to
surgeon and anestesiologist preference. In the second part
of our study, all the consecutive TIVADs were inserted
using the ultrasound technique. The anatomical choice
for venous access is shown in Table 3. In the surgical cut-
down technique, the cephalic vein was used in almost all
cases (92/102 patients), in the rest of the cases (10 pa-
tients) the external jugular vein was used. The access site
for blind cutaneus technique was the subclavian vein in 41
cases or the jugular vein in 5 cases (2 cases missing). The
majority of the access sites were, the distal internal jugular
Table 4 Early complications divided in groups according to the implantation technique (Intention To Treat)
Complication Surgical cutdown
(102 pts) SC












(646 pts) US SC vs BP BP vs US SC vs US
Pneumothorax 0 (0%) 4 (8.3%) 0 (0%) 0.009 <0.001 NA
Arterial puncture 0 (0%) 4 (8.3%) 8 (1.2%) 0.009 0.006 0.390
Arrhythmia 0 (0%) 1 (2.1%) 2 (0.3%) 0.301 0.193 0.179
Technique failure 15 (14.7%) 3 (6.2%) 2 (0.3%) 0.181 0.002 <0.001
Access site change after
first attempt 0 (0%) 5 (10.4%) 13 (2%)
0.002 0.005 0.233
Total 15 (14.7%) 17 (35.4%) 25 (3.9%) 0.005 <0.001 <0.001
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approach (515/646 patients), then the subclavian vein (29
cases) or the distal internal jugular vein (100 cases).
Clinical outcome
In 102 patients placement of TIVAD via the cephalic
vein cutdown approach was initially attempted, 87 pa-
tients underwent successful insertion while 15 required
conversion to a percutaneous approach (success rate
85.3%), 11 using the blind technique, 3 using the ultra-
sound guided technique. In one patient, it was impos-
sible to access any central vein due to the anatomical
pitfalls and a peripheral inserted central venous access
(PICC) was inserted under ultrasound guidance. Lack of
success was related to small size of vein (n = 6) or inabil-
ity to locate the vein (n = 8) or impossibility to trans-
verse the angle of insertion of cephalic vein into the
subclavian vein (n = 1). The percutaneous blind tech-
nique was initially used in 48 patients, and was success-
ful in 45 patients (93.7%), 3 patients required conversion
to a surgical approach. Lack of success was related to
occurrence of pneumothorax attempting subcavian vein
cannulation (n = 2) or inability to locate the vein (n = 1).
The ultrasound guided approach was used as a primary
technique in 646 patients with a success rate of 99.7%
(644/646). In 13 patients, a second attempt changingTable 5 Late complications divided in groups according to th
Surgical cutdown Blind percutaneous US guid
(102 pts) SC (48 pts) BP (646 pt
Complication Removal Removal Remova
Sepsis 11 (10.8%) 0 (0%) 18 (2.8%
Thrombosis 2 (1.9%) 0 (0%) 1 (0.1%)
Dislocation 1 (0.9%) 2 (4.1%) 4 (0.6%)
Dehiscence 0 (0%) 0 (0%) 3 (0.5%)
Severe pain 0 (0%) 0 (0%) 1 (0.1%)
Total 14 (13.7%) 3 (6.2%) 26 (4.0%puncture site was necessary, while 2 patients required
conversion to a surgical approach because of fibrotic or
collapsed vein. Mean operating time was 51 minutes for
cephalic vein cutdown approach, 49 minutes for blind
percutaneous technique and 33 minutes for ultrasound
guided technique.
The cost, expressed as cost of time of use of the opera-
tive room of US-guided TIVAD placement, was signifi-
cantly lower compared to cutdown approach and to
percutaneous blind technique. In fact, in spite of the use
of the same device, the duration of the procedure was
significantly shorter in patients who had a US guided
TVAD placement.
The overall early complication rate including changing
the puncture site using then same technique was 7.2% (57
of 796 cases) as listed in Table 4. The only severe intraoper-
ative complications requiring immediate treatment were
three of the four pneumothoraxes and one of the two ar-
rhythmias (a supraventricular paroxistic tachycardia requir-
ing pharmacological treatment). All the other complications
did not require any treatment except for a longer monitor-
ing before discharge. The technique failure was significantly
reduced using ultrasound compared with the surgical tech-
nique (p < 0,001). The occurrence of pneumothorax and ar-
terial puncture were significantly higher in the landmark
group as compared to the ultrasound group. Interestingly,e implantation technique (Intention to treat)






s) US SC vs BP BP vs US SC vs US
l
) 0.016 0.392 <0.001




) 0.269 0.713 <0.001
Table 6 Predictors of late complications
Variable Predictors Odds ratio 95% CI p-value
Removal for sepsis Surgical isolation 2,706 0,9955 - 7,3546 0,051
p = 0,0838 Current CT 0,799 0,3102 - 2,0599 0,643
BMI 1,002 0,9940 - 1,0109 0,570
Head and neck cancer 3,045 0,6287 - 14,7470 0,167
WBC count 0,817 0,6682 - 0,9976 0,047
Removal for DVT Anticoagulant or antiaggregant therapy 16,410 0,5533 - 486,6924 0,106
p = 0,0273 Surgical isolation 45,218 1,5944 - 1282,4410 0,026
Removal for dislocation US guided puncture 0,320 0,0699 - 1,4626 0,142
p = 0,2947 Difficult puncture 1,318 0,5202 - 3,3380 0,561
Granziera et al. BMC Surgery 2014, 14:27 Page 6 of 9
http://www.biomedcentral.com/1471-2482/14/27our data shows a significantly increased number of sepsis in
the surgical group compared with those documented in the
ultrasound group, although the overall rate of late compli-
cations was significantly lower in this group.
Late complications occurred in 49 of 796 patients
(6.1%), requiring removal of the TIVAD in 43 (5.2%) as
listed in Table 5. The microorganisms isolated in TIVAD
related sepsis were candida glabrata, candida parapsilo-
sis, bacillus species, streptococcus mitis, pseudomanas
aeruginosa, and staphylococcus epidermidis. The other
cases of late complications that did not require removal
of the TIVAD were: one case of sepsis treated with intra-
venous antibiotics, one thrombosis that required antico-
agulants with remission, one malfunction, 2 cases of
extravasation or severe pain. As shown in Table 6, we
performed a logistic regression for prediction of late
complications that lead to TIVAD removal. Only the
open approach and low levels of white blood cells
resulted to be independent predictor of urgent TIVAD
removal. Risk rate analysis of TIVAD removal for sepsisFigure 1 Risk analysis for TIVAD urgent removal.showed a peak between 20 and 30 weeks and a second
one after 60 weeks DVT, decubitus and dislocation had
a risk rate peak after 60 weeks. Risk analysis for TIVAD
urgent removal is shown in Figure 1. Late misplacement
of TIVAD occurred but they did not require any further
intervention unless it precluded its function. Some
misplacement cases are shown in Figure 2.
Discussion
Different and long term chemotherapy treatments or
nutritional support require a long term venous access in a
cancer patient. Since 1982, the increasingly frequent use
of TIVADs has reduced the burden of peripheral vein
complications and the restriction on physical activities of
patients and, thus, improving quality of life. On the other
hand, there is a strict association between the incidence of
TIVAD-related complications and the occurrence of psy-
chosocial complaints (eg, depression, fatigue, social im-
pairment, and decreased quality of life) [15]. Ideally,
TIVAD positioning should have a low rate of morbidity
Figure 2 Late TIVAD misplacement that did not compromise their function.
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be easily tolerable for the patient during his daily routine.
In our retrospective series, three different implantation
techniques were used and compared in order to identify
the technique that may guarantee the best outcome.
In our series, the overall complication rate is consist-
ent with data reported by several studies [4,16-18], that
range between 2 to 14.4%. Furthermore, similarly to
recent series, we observed a decreasing trend for early
complications. Rare major complication as described in
previous studies or case series reports, such as hemotho-
rax [19], air embolism [20], pericardial tamponade [21]
and brachial plexus injury [22] did not occur in our
series. At the beginning of our experience, the surgical
cutdown technique in cephalic vein was used and it had
the advantage of no early complications but at the price
of a higher technical failure rate. Nevertheless, the com-
plications rate did not seem to be correlated with the ex-
perience of the operator [6,7,23]. In our series, 4 cases of
pneumothoraxes occurred after the blind percutaneous
technique and, three of them needed to be treated with
a chest drain tube. Pneumothorax seems to be the most
frequent and important complication after insertion,
with an immediate clinical impact. Its incidence varies
between 0.5-6% [24], highly correlated with the blind
subclavicular approach and with the multiple attempts
of needle passage. In our series, US-guided insertion
completely eliminated this complication probably be-
cause it provides a direct visualization of the needle and
all the underlying anatomical structures during the
whole procedure. Although accidental arterial puncture
seems to occur mainly during subclavicular approach
with a frequency between 6-8% [8], in our series we ob-
served 8 accidental artery puncture of the ultrasound
guided approach group occurred during the “learning
curve” period of the technique (first 3 months). How-
ever, they did not require any treatment except for a lon-
ger monitoring before discharge.According to the results of this study, the occurrence of
these complications was reduced by limiting the number
of needle passages with ultrasonic identification of the
vein. Indeed, this technique permitted to obtain a signifi-
cantly lower rate of technical failure without changing the
access site for TIVAD implantation. A further benefit
from two dimensional US guidance for central venous ac-
cess compared with the other methods was a faster access.
In fact, the operating time was significantly shorter in the
ultrasound group compared to the others. As demon-
strated in a meta analysis investigating ultrasound guid-
ance [25], data reflected on cost effectiveness. The
resource saving is obtained by shortening the time spent
by clinicians and nurses to achieve successful cannulation
and to deal with complications. This time saving proced-
ure reduced the use of expensive operative room time.
In our series, surgical cutdown technique in cephalic
vein and low levels of white blood cells resulted to be a
significant predictor of TIVAD removal for complication.
In the series described by Mansfield et al., the factor asso-
ciated to early complications after TIVAD placement are
prior attempts or catheterisation of the vein, local modifi-
cation due to previous radiotherapy, a high body mass
index and multiple needle passages on the puncture site
[26]. The difference of the predictors of TIVAD complica-
tion may be ascribed to the different techniques adopted
in the two series: in our series the prevalent access was
the US guided through internal jugular vein compared to
the subclavicular access used in the Mansfield series.
The infection of the pocket was the most frequent late
complications and the main cause of TIVAD removal in
our series. Similarly, in the series described by Koch et al.,
this complication occurred in around 5% of all cases [5].
In fact, the infection of the pocket occurred more often
after 20 weeks and after 60 weeks and this observation
suggests that the postoperative infection is extremely rare
and the causes are mainly related to its use (20 weeks
peak) or lack of monthly maintenance (60 weeks peak).
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were not more prone to infection and TIVAD extraction.
The second most important complication, thrombosis,
can occur in around 4.7 to 8.46% [27,28] but in our series
it was much less frequent probably because of the regular
rinsing of the catheter with heparin. Catheter malfunction
can be caused mainly by the formation of a fibrin sheath
that functions as a one-way valve in over 50% of all cases
and by intraluminal thrombotic occlusion in 2-3%. Finally
in our series, we did not observe any late complications
such as: catheter rupture or migration, pinch-off syn-
drome, erosion with perforation of superior vein cava.
The main limit of this study is its retrospective design.
Nevertheless, this limit was in part ridden over by the
use of a prospectively collected database. The second
limit of this study was the different sample size of the
three groups. In fact, the first two groups are smaller
than the last one. However, the overall sample size of
the three groups was sufficient to make adequate com-
parison. Although our study provides a good definition
of pro and cons of the different techniques a proper
randomized controlled trial should be warranted to def-
initely determine the best TIVAD insertion technique.
Conclusions
In conclusion, the results of our study demonstrate that
ultrasound guided percutaneous technique is the safest
and the most cost effective method for TIVAD insertion.
In fact, the overall early complications rate was significantly
lower for the ultrasound technique and, in particular, there
was a significant reduction of the risk of pneumothorax.
In order to reduce the immediate complication rate on
TIVAD insertion, a real time US-guided technique should
be preferred for vein identification and for puncture guid-
ance and this technique may be assumed as standard care
in case of TIVAD placement.
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